Effects of sFlt-1 and alpha 2-macroglobulin on vascular endothelial growth factor-induced endothelin-1 upregulation in human microvascular endothelial cells

Placenta

Volumn 35, Issue 1, 2014, Pages 64-69

  Yi, K W ^a   Jung, S H ^b   Cho, G J ^a   Seol, H J ^c   Hong, S C ^a   Oh, M J ^a   Kim, H J ^a  

^a Korea University College of Medicine   (South Korea)

^b Paediatric Emergency Centre   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

Author keywords

Endothelin 1; Preeclampsia; sFlt 1

Indexed keywords

ALPHA 2 MACROGLOBULIN; ENDOTHELIN 1; MESSENGER RNA; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BIOLOGICAL ACTIVITY; CELL COUNT; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MICROVASCULAR ENDOTHELIAL CELL; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ENDOTHELIN-1; PREECLAMPSIA; SFLT-1; Α(2)-MACROGLOBULIN;

ALPHA-MACROGLOBULINS; ENDOTHELIAL CELLS; ENDOTHELIN-1; FEMALE; HUMANS; RNA, MESSENGER; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84896542289     PISSN: 01434004     EISSN: 15323102     Source Type: Journal    
DOI: 10.1016/j.placenta.2013.09.008     Document Type: Article

References (35)

1. I.A. Brosens Morphological changes in the utero-placental bed in pregnancy hypertension Clin Obstet Gynaecol 4 1977 573 593
2. J.M. Roberts, R.N. Taylor, T.J. Musci, G.M. Rodgers, C.A. Hubel, and M.K. McLaughlin Preeclampsia: an endothelial cell disorder Am J Obstet Gynecol 161 1989 1200 1204
3. S. Nishikawa, A. Miyamoto, H. Yamamoto, H. Ohshika, and R. Kudo The relationship between serum nitrate and endothelin-1 concentrations in preeclampsia Life Sci 67 2000 1447 1454
4. R.N. Taylor, M. Varma, N.N. Teng, and J.M. Roberts Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies J Clin Endocrinol Metab 71 1990 1675 1677
5. B. Baksu, I. Davas, A. Baksu, A. Akyol, and G. Gulbaba Plasma nitric oxide, endothelin-1 and urinary nitric oxide and cyclic guanosine monophosphate levels in hypertensive pregnant women Int J Gynaecol Obstet 90 2005 112 117
6. M. Faxen, J. Nasiell, N.O. Lunell, and A. Blanck Differences in mRNA expression of endothelin-1, c-fos and c-jun in placentas from normal pregnancies and pregnancies complicated with preeclampsia and/or intrauterine growth retardation Gynecol Obstet Invest 44 1997 93 96
7. J.C. Brockelsby, F.W. Anthony, I.R. Johnson, and P.N. Baker The effects of vascular endothelial growth factor on endothelial cells: a potential role in preeclampsia Am J Obstet Gynecol 182 2000 176 183
8. Seol HJ, Oh MJ, Kim HJ. Endothelin-1 expression by vascular endothelial growth factor in human umbilical vein endothelial cells and aortic smooth muscle cells. Hypertens Pregnancy 30:295-301.
9. K.J. Lee, M.K. Kim, Y.H. Park, H.J. Seol, J.E. Lim, and J.N. Lee et al. Vascular endothelial growth factor induces endothelin-1 production via matrix metalloproteinase-2 rather than endothelin-converting enzyme-1 Hypertens Pregnancy 26 2007 189 199
10. S.E. Maynard, J.Y. Min, J. Merchan, K.H. Lim, J. Li, and S. Mondal et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J Clin Invest 111 2003 649 658
11. F. Kabbinavar, H.I. Hurwitz, L. Fehrenbacher, N.J. Meropol, W.F. Novotny, and G. Lieberman et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 2003 60 65
12. J.C. Yang, L. Haworth, R.M. Sherry, P. Hwu, D.J. Schwartzentruber, and S.L. Topalian et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
13. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676
14. G. Bhattacharjee, I.R. Asplin, S.M. Wu, G. Gawdi, and S.V. Pizzo The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding J Biol Chem 275 2000 26806 26811
15. C.M. Petersen Alpha 2-macroglobulin and pregnancy zone protein. Serum levels, alpha 2-macroglobulin receptors, cellular synthesis and aspects of function in relation to immunology Dan Med Bull 40 1993 409 446
16. G.C. McKeeman, J.E. Ardill, C.M. Caldwell, A.J. Hunter, and N. McClure Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop Am J Obstet Gynecol 191 2004 1240 1246
17. S. Ahmad, and A. Ahmed Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia Circ Res 95 2004 884 891
18. T. Chaiworapongsa, R. Romero, J. Espinoza, E. Bujold, Y. Mee Kim, and L.F. Goncalves et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award Am J Obstet Gynecol 190 2004 1541 1547 discussion 1547-50
19. E.S. Lee, M.J. Oh, J.W. Jung, J.E. Lim, H.J. Seol, and K.J. Lee et al. The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia J Korean Med Sci 22 2007 94 98
20. E. Shibata, A. Rajakumar, R.W. Powers, R.W. Larkin, C. Gilmour, and L.M. Bodnar et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor J Clin Endocrinol Metab 90 2005 4895 4903
21. T. Chaiworapongsa, R. Romero, Y.M. Kim, G.J. Kim, M.R. Kim, and J. Espinoza et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia J Matern Fetal Neonatal Med 17 2005 3 18
22. A. Hertig, N. Berkane, G. Lefevre, K. Toumi, H.P. Marti, and J. Capeau et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia Clin Chem 50 2004 1702 1703
23. R.J. Levine, S.E. Maynard, C. Qian, K.H. Lim, L.J. England, and K.F. Yu et al. Circulating angiogenic factors and the risk of preeclampsia N Engl J Med 350 2004 672 683
24. J. LaMarre, G.K. Wollenberg, S.L. Gonias, and M.A. Hayes Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins Lab Invest 65 1991 3 14
25. J.S. Huang, S.S. Huang, and T.F. Deuel Specific covalent binding of platelet-derived growth factor to human plasma alpha 2-macroglobulin Proc Natl Acad Sci U S A 81 1984 342 346
26. E.W. Raines, D.F. Bowen-Pope, and R. Ross Plasma binding proteins for platelet-derived growth factor that inhibit its binding to cell-surface receptors Proc Natl Acad Sci U S A 81 1984 3424 3428
27. D. Danielpour, and M.B. Sporn Differential inhibition of transforming growth factor beta 1 and beta 2 activity by alpha 2-macroglobulin J Biol Chem 265 1990 6973 6977
28. D.J. Webb, J. Wen, L.R. Karns, M.G. Kurilla, and S.L. Gonias Localization of the binding site for transforming growth factor-beta in human alpha2-macroglobulin to a 20-kDa peptide that also contains the bait region J Biol Chem 273 1998 13339 13346
29. S. Soker, C.M. Svahn, and G. Neufeld Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin J Biol Chem 268 1993 7685 7691
30. J. Brockelsby, R. Hayman, A. Ahmed, A. Warren, I. Johnson, and P. Baker VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy: implications in the pathogenesis of preeclampsia Lab Invest 79 1999 1101 1111
31. E. Svedas, K.B. Islam, H. Nisell, and K.R. Kublickiene Vascular endothelial growth factor induced functional and morphologic signs of endothelial dysfunction in isolated arteries from normal pregnant women Am J Obstet Gynecol 188 2003 168 176
32. A. Matsuura, W. Yamochi, K. Hirata, S. Kawashima, and M. Yokoyama Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression Hypertension 32 1998 89 95
33. A. Matsuura, S. Kawashima, W. Yamochi, K. Hirata, T. Yamaguchi, and N. Emoto et al. Vascular endothelial growth factor increases endothelin-converting enzyme expression in vascular endothelial cells Biochem Biophys Res Commun 235 1997 713 716
34. S. Zucker, H. Mirza, C.E. Conner, A.F. Lorenz, M.H. Drews, and W.F. Bahou et al. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation Int J Cancer 75 1998 780 786
35. C. Fernandez-Patron, M.W. Radomski, and S.T. Davidge Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor Circ Res 85 1999 906 911